Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 Phase 2b study in active cutaneous lupus erythematosus
2024-516745-39-00Phase 2Completed
- Sponsor
- Immunovant, Inc.
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) comparing IMVT-1402 with Placebo (2 arms). Primary endpoint: Percent change from Period 1 baseline in CLASI-A score at Week 12. Started Jul 2025; status: completed.
02
Drugs
IMVT-1402
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on 2024-516745-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516745-39-00.